Virginie D.

Virginie D. is a seasoned professional in product development and program management with extensive experience in the pharmaceutical industry. Currently serving as Senior Director at Neuren Pharmaceuticals Limited since March 2021, Virginie D. leads the development of innovative therapies for neurodevelopmental disorders, notably overseeing the phase 2 trials of NNZ-2591 and the pivotal phase 3 trial of Trofinetide for Rett syndrome. Prior to this role, Virginie D. held significant positions at Pfizer from September 2015 to December 2020, including Pipeline Development Lead and Senior Global Program Manager, where responsibilities included managing complex product development and lifecycle strategies. Virginie D.'s earlier career at Hospira and Mayne Pharma involved overseeing pipeline development, leading global product initiatives, and enhancing operational efficiencies. Educational qualifications include an MBA from the Australian Graduate School of Entrepreneurship and degrees in Chemical Engineering and Chemistry from French universities.